Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study
文献类型：期刊论文
| 作者 | Liu, Haixia6; Yu, Rui5; Gao, Yanan5; Li, Xirong6; Guan, Xiaoni4; Thomas, Kosten2,3; Xiu, Meihong4; Zhang, Xiangyang1
|
| 刊名 | CURRENT NEUROPHARMACOLOGY
 |
| 出版日期 | 2022 |
| 卷号 | 20期号:9页码:1774-1782 |
| 关键词 | Schizophrenia antioxidant oxidative stress weight gain risperidone antioxidant enzyme activities |
| ISSN号 | 1570-159X |
| DOI | 10.2174/1570159X19666210920090547 |
| 通讯作者 | Xiu, Meihong(xiumeihong9797@gmail.com) ; Zhang, Xiangyang() |
| 英文摘要 | Background: Oxidative stress plays an important role in weight gain induced by antipsychotics in schizophrenia (SCZ). However, little is known about how antioxidant enzymes are involved in weight gain caused by risperidone monotherapy in antipsychotics-naive first-episode (ANFE) patients with SCZ. Therefore, the main purpose of this study was to investigate the effects of risperidone on several antioxidant enzymes in patients with ANFE SCZ and the relationship between weight gain and changes in antioxidant enzyme activities. Objective: The activities of plasma superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as the levels of malondialdehyde (MDA) were measured in 225 ANFE patients and 125 healthy controls. Methods: Patients were treated with risperidone monotherapy for 12 weeks. Clinical symptoms, antioxidant enzyme activities, and MDA levels were measured at baseline and during follow-up. Results: Compared with healthy controls, the patients showed higher activities of SOD and CAT but lower MDA levels and GPx activity. At baseline, the CAT activity was associated with body weight or BMI. Further, based on a 7% weight increase from baseline to follow-up, we found 75 patients in the weight gain (WG) group and 150 patients in the non-WG group. Comparing SOD, CAT, GPx activities and MDA levels between the WG group and the non-WG group at baseline and during the 12-week follow-up, it was found that after treatment, the SOD activity in the WG group increased while the MDA level decreased in the non-WG group. Moreover, baseline SOD and GPx activities were predictors of weight gain at 12-week follow-up. Conclusion: These results suggest that the antioxidant defense system may have predictive value for the weight gain of ANFE SCZ patients after risperidone treatment. |
| 收录类别 | SCI |
| WOS关键词 | INCREASED OXIDATIVE STRESS ; ANTIPSYCHOTIC-DRUGS ; SUPEROXIDE-DISMUTASE ; OBESITY ; CLOZAPINE ; MECHANISMS ; CAPACITY ; RADICALS ; DEFENSE ; MODEL |
| 资助项目 | CAS Pioneer Hundred Talents Program |
| WOS研究方向 | Neurosciences & Neurology ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000843817800011 |
| 出版者 | BENTHAM SCIENCE PUBL LTD |
| 资助机构 | CAS Pioneer Hundred Talents Program |
| 源URL | [http://ir.psych.ac.cn/handle/311026/43269]  |
| 专题 | 心理研究所_中国科学院心理健康重点实验室 |
| 通讯作者 | Xiu, Meihong; Zhang, Xiangyang |
| 作者单位 | 1.Chinese Acad Sci, Inst Psychol, CAS Key Lab Mental Hlth, Beijing, Peoples R China 2.Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA 3.Michael E DeBakey VA Med Ctr, Mental Hlth Care Line, Houston, TX USA 4.Peking Univ, Beijing HuiLongGuan Hosp, HuiLong Guan Clin Med Sch, Beijing, Peoples R China 5.Qingdao Univ, Qingdao Mental Hlth Ctr, Qingdao, Peoples R China 6.Shandong Mental Hlth Ctr, Dept Psychiat, Jinan, Peoples R China |
| 推荐引用方式 GB/T 7714 | Liu, Haixia,Yu, Rui,Gao, Yanan,et al. Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study[J]. CURRENT NEUROPHARMACOLOGY,2022,20(9):1774-1782. |
| APA | Liu, Haixia.,Yu, Rui.,Gao, Yanan.,Li, Xirong.,Guan, Xiaoni.,...&Zhang, Xiangyang.(2022).Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study.CURRENT NEUROPHARMACOLOGY,20(9),1774-1782. |
| MLA | Liu, Haixia,et al."Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study".CURRENT NEUROPHARMACOLOGY 20.9(2022):1774-1782. |
入库方式： OAI收割
来源：心理研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。